228 related articles for article (PubMed ID: 31529048)
41. Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors.
Majós C; Pons-Escoda A; Naval P; Güell A; Lucas A; Vidal N; Cos M; Bruna J
Eur Radiol; 2024 Apr; 34(4):2174-2182. PubMed ID: 37740778
[TBL] [Abstract][Full Text] [Related]
42. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
43. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract][Full Text] [Related]
44. Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of
Yamamura T; Tamura K; Kobayashi D; Inaji M; Toyama Y; Wakimoto H; Kiyokawa J; Hara S; Tanaka Y; Nariai T; Shimizu K; Ishii K; Maehara T
J Neurooncol; 2024 Jun; 168(2):355-365. PubMed ID: 38557927
[TBL] [Abstract][Full Text] [Related]
45. Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor.
Zhao B; Xia Y; Yang F; Wang Y; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Mol Med; 2022 Mar; 28(1):34. PubMed ID: 35287567
[TBL] [Abstract][Full Text] [Related]
46. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
47. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.
Weller M; Felsberg J; Hentschel B; Gramatzki D; Kubon N; Wolter M; Reusche M; Roth P; Krex D; Herrlinger U; Westphal M; Tonn JC; Regli L; Maurage CA; von Deimling A; Pietsch T; Le Rhun E; Reifenberger G
Acta Neuropathol; 2024 Jan; 147(1):11. PubMed ID: 38183430
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
Varughese RK; Skjulsvik AJ; Torp SH
Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
[TBL] [Abstract][Full Text] [Related]
49. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
50. Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
Roberts KF; Dahiya SM
Neuro Oncol; 2023 Aug; 25(8):1450-1451. PubMed ID: 37097042
[No Abstract] [Full Text] [Related]
51. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
Kuwahara K; Ohba S; Nakae S; Hattori N; Pareira ES; Yamada S; Sasaki H; Abe M; Hasegawa M; Hirose Y
Brain Tumor Pathol; 2019 Oct; 36(4):135-143. PubMed ID: 31324999
[TBL] [Abstract][Full Text] [Related]
52. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
53. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
[TBL] [Abstract][Full Text] [Related]
54. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
55. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.
Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A
Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032
[No Abstract] [Full Text] [Related]
56. Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settings.
Suman S; Sharma R; Katiyar V; Mahajan S; Suri A; Sharma MC; Sarkar C; Suri V
Neurosurg Focus; 2022 Dec; 53(6):E17. PubMed ID: 36455270
[TBL] [Abstract][Full Text] [Related]
57. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W
Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984
[TBL] [Abstract][Full Text] [Related]
58. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
[TBL] [Abstract][Full Text] [Related]
59. [Analysis of the clinical impact of the diagnostic reclassification of brain gliomas according to the World Health Organization classification (2016)].
Mateo-Sierra O; Alcalá-Torres J; Serret-De Troya C; Valera-Melé M; Solá-Vendrell E
Rev Neurol; 2019 Nov; 69(10):402-408. PubMed ID: 31713226
[TBL] [Abstract][Full Text] [Related]
60. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
